Wake Forest Institute for Regenerative Medicine (WFIRM) scientists have improved upon the 3-D bioprinting technique they developed to engineer skeletal muscle as a potential therapy for replacing diseased or damaged muscle tissue, moving another step closer to someday being able to treat patients.
Skeletal muscles are attached to bones by tendons and are responsible for the body’s movement. When they are damaged, there is often loss of muscle function because the nerves are no longer sending signals to the brain.
Treatment of extensive muscle defect injuries like those caused by improvised explosive devices (IEDs) on the battlefield, for instance, is difficult and often requires reconstructive surgery with muscle grafts. Effective nerve integration of bioengineered skeletal muscle tissues has been a challenge.
“Being able to bioengineer implantable skeletal muscle constructs that mimics the native muscle to restore function represents a significant advance in treating these types of injuries,” said lead author Ji Hyun Kim, Ph.D., of WFIRM. “Our hope is to develop a therapeutic option that will help heal injured patients and give them back as much function and normalcy as possible.”
The work is detailed in a paper published online today by the journal Nature Communications.
Institute scientists previously demonstrated that the Integrated Tissue and Organ Printing System (ITOP), developed in house over a 14-year period, can generate organized printed muscle tissue that is robust enough to maintain its structural characteristics.
Since then, the WFIRM researchers have been developing and testing different types of skeletal muscle tissue constructs to find the right combination of cells and materials to achieve functional muscle tissue. In the current study, they investigated the effects of neural cell integration into the bioprinted muscle construct to accelerate functional muscle regeneration.
“These constructs were able to facilitate rapid nerve distribution and matured into organized muscle tissue that restored normal muscle weight and function in a pre-clinical model of muscle defect injury,” said Sang Jin Lee, Ph.D., co-senior author, also of WFIRM.
This ongoing line of research at WFIRM is supported and federally funded through the Armed Forces Institute of Regenerative Medicine. The goal is to develop clinical therapies to treat wounded warriors that will also benefit the civilian population.
“Continued improvements in 3-D bioprinting techniques and materials are helping us advance in our quest to make replacement tissue for patients,” said co-senior author Anthony Atala, M.D., who is director of WFIRM.